Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript – Seeking Alpha

Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript
Seeking Alpha
On the next program, I would like to talk about is PL-3994, our natriuretic peptide receptor agonist in development as a treatment for acute exacerbations of asthma. Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 ResultsPR Newswire (press release)

all 20 news articles »

View full post on asthma – Google News